SCHIZOPHRENIA

Enrollment Pending for Phase 2 Study

Enrollment is pending for our Phase 2 study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

FOR OUR UPCOMING CLINICAL TRIAL IN AUSTRALIA:

NCT06442462
Status: not yet recruiting; please continue to check the status at ClinicalTrials.gov

Location
MAPrc, Melbourne VIC, Australia

Contact: Emorfia Gavrilidis at MAPrc 
emmy.gavrilidis@monash.edu

 

For additional information, visit ClinicalTrials.gov